Nuevos fármacos para el tratamiento de la hipercolesterolemia

Statins are the preferred treatment for hypercholesterolemia and several studies have demonstrated their long-term safety and efficacy in reducing cardiovascular morbidity and mortality. However, in some cases of severe hypercholesterolemia such as homozygous and heterozygous familial hypercholester...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cuevas,Ada, Farías,María Magdalena, Alonso,Rodrigo
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2014
Materias:	Anticholesteremic agents Hypercholesterolemia, familial combined Lipido-lowering therapy Lomitapide Mipomersen
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872014000700008
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872014000700008
record_format	dspace
spelling	oai:scielo:S0034-988720140007000082014-12-10Nuevos fármacos para el tratamiento de la hipercolesterolemiaCuevas,AdaFarías,María MagdalenaAlonso,Rodrigo Anticholesteremic agents Hypercholesterolemia, familial combined Lipido-lowering therapy Lomitapide Mipomersen Statins are the preferred treatment for hypercholesterolemia and several studies have demonstrated their long-term safety and efficacy in reducing cardiovascular morbidity and mortality. However, in some cases of severe hypercholesterolemia such as homozygous and heterozygous familial hypercholesterolemia or statin intolerant patients, statins can be less efficient. In recent years, new lipid-lowering agents with novel mechanisms of action have been developed to reduce LDL-cholesterol in patients with severe hypercholesterolemia, associated or not to conventional lipid-lowering therapy. These therapies include microsomal transfer protein inhibitor (Lomitapide), antisense oligonucleotide to Apo B100 (Mipomersen) and monoclonal antibodies against Proprotein convertase subtilisin/kexin type 9 (PCSK9). Different studies have shown the great effectiveness of these new therapies. Short-term studies confirmed their adequate security profile, especially in patients with homozygous familiar hypercholesterolemia or severe hypercholesterolemia. Some of these agents have been also tested in statin-intolerant patients. However, long-term studies are needed to evaluate their safety, effectiveness and impact on cardiovascular risk reduction.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.142 n.7 20142014-07-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872014000700008es10.4067/S0034-98872014000700008
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Anticholesteremic agents Hypercholesterolemia, familial combined Lipido-lowering therapy Lomitapide Mipomersen
spellingShingle	Anticholesteremic agents Hypercholesterolemia, familial combined Lipido-lowering therapy Lomitapide Mipomersen Cuevas,Ada Farías,María Magdalena Alonso,Rodrigo Nuevos fármacos para el tratamiento de la hipercolesterolemia
description	Statins are the preferred treatment for hypercholesterolemia and several studies have demonstrated their long-term safety and efficacy in reducing cardiovascular morbidity and mortality. However, in some cases of severe hypercholesterolemia such as homozygous and heterozygous familial hypercholesterolemia or statin intolerant patients, statins can be less efficient. In recent years, new lipid-lowering agents with novel mechanisms of action have been developed to reduce LDL-cholesterol in patients with severe hypercholesterolemia, associated or not to conventional lipid-lowering therapy. These therapies include microsomal transfer protein inhibitor (Lomitapide), antisense oligonucleotide to Apo B100 (Mipomersen) and monoclonal antibodies against Proprotein convertase subtilisin/kexin type 9 (PCSK9). Different studies have shown the great effectiveness of these new therapies. Short-term studies confirmed their adequate security profile, especially in patients with homozygous familiar hypercholesterolemia or severe hypercholesterolemia. Some of these agents have been also tested in statin-intolerant patients. However, long-term studies are needed to evaluate their safety, effectiveness and impact on cardiovascular risk reduction.
author	Cuevas,Ada Farías,María Magdalena Alonso,Rodrigo
author_facet	Cuevas,Ada Farías,María Magdalena Alonso,Rodrigo
author_sort	Cuevas,Ada
title	Nuevos fármacos para el tratamiento de la hipercolesterolemia
title_short	Nuevos fármacos para el tratamiento de la hipercolesterolemia
title_full	Nuevos fármacos para el tratamiento de la hipercolesterolemia
title_fullStr	Nuevos fármacos para el tratamiento de la hipercolesterolemia
title_full_unstemmed	Nuevos fármacos para el tratamiento de la hipercolesterolemia
title_sort	nuevos fármacos para el tratamiento de la hipercolesterolemia
publisher	Sociedad Médica de Santiago
publishDate	2014
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872014000700008
work_keys_str_mv	AT cuevasada nuevosfarmacosparaeltratamientodelahipercolesterolemia AT fariasmariamagdalena nuevosfarmacosparaeltratamientodelahipercolesterolemia AT alonsorodrigo nuevosfarmacosparaeltratamientodelahipercolesterolemia
_version_	1718436766425284608

Nuevos fármacos para el tratamiento de la hipercolesterolemia

Ejemplares similares